ATE402169T1 - Quinazolin-derivate als kinase inhibitoren - Google Patents

Quinazolin-derivate als kinase inhibitoren

Info

Publication number
ATE402169T1
ATE402169T1 AT01964612T AT01964612T ATE402169T1 AT E402169 T1 ATE402169 T1 AT E402169T1 AT 01964612 T AT01964612 T AT 01964612T AT 01964612 T AT01964612 T AT 01964612T AT E402169 T1 ATE402169 T1 AT E402169T1
Authority
AT
Austria
Prior art keywords
kinases
phosphorylation
pharmaceutically acceptable
acceptable salts
kinase inhibitors
Prior art date
Application number
AT01964612T
Other languages
English (en)
Inventor
Anjali Pandey
Robert Scarborough
Kenji Matsuno
Michio Ichimura
Yuji Nomoto
Shinichi Ide
Eiji Tsukuda
Junko Irie
Shoji Oda
Original Assignee
Millennium Pharm Inc
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc, Kyowa Hakko Kogyo Kk filed Critical Millennium Pharm Inc
Application granted granted Critical
Publication of ATE402169T1 publication Critical patent/ATE402169T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
AT01964612T 2000-08-18 2001-08-17 Quinazolin-derivate als kinase inhibitoren ATE402169T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22612200P 2000-08-18 2000-08-18

Publications (1)

Publication Number Publication Date
ATE402169T1 true ATE402169T1 (de) 2008-08-15

Family

ID=22847639

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01964612T ATE402169T1 (de) 2000-08-18 2001-08-17 Quinazolin-derivate als kinase inhibitoren

Country Status (25)

Country Link
US (5) US6982266B2 (de)
EP (3) EP2277877A1 (de)
JP (1) JP5073147B2 (de)
KR (1) KR100831116B1 (de)
CN (1) CN100358890C (de)
AT (1) ATE402169T1 (de)
AU (1) AU8544901A (de)
BR (1) BR0113356A (de)
CA (1) CA2426440C (de)
CY (1) CY1110460T1 (de)
CZ (1) CZ304061B6 (de)
DE (1) DE60134990D1 (de)
DK (1) DK1315715T3 (de)
EA (1) EA005809B1 (de)
ES (1) ES2311023T3 (de)
HK (1) HK1057206A1 (de)
HU (1) HU228668B1 (de)
IL (2) IL154514A0 (de)
MX (1) MXPA03001359A (de)
NO (1) NO323782B1 (de)
NZ (1) NZ524461A (de)
PT (1) PT1315715E (de)
SI (1) SI1315715T1 (de)
WO (1) WO2002016351A1 (de)
ZA (1) ZA200301510B (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001293209A1 (en) 2000-08-18 2002-03-04 Cor Therapeutics, Inc. Nitrogenous heterocyclic compounds
EP1309568B1 (de) 2000-08-18 2011-02-16 Millennium Pharmaceuticals, Inc. (Chinazolin-4-yl)piperazin-4-yl]thiocarboxamide als Hemmer der Phosphorylierung eines PDGF-Rezeptors
EP2277877A1 (de) * 2000-08-18 2011-01-26 Millennium Pharmaceuticals, Inc. Quinazolinderivate als Kinasehemmer
WO2002036587A2 (en) 2000-11-01 2002-05-10 Cor Therapeutics, Inc. Process for the production of 4-quinazolinylpiperazin-1-carboxylic acid phenylamides
AU2002254152A1 (en) 2001-03-08 2002-09-24 Millennium Pharmaceuticals (homo) piperazine substituted quinolines for inhibiting the phosphorylation of kinases
HUP0500111A3 (en) 2001-12-27 2009-10-28 Theravance Indolinone derivatives useful as protein kinase inhibitors
AU2003256922A1 (en) * 2002-07-31 2004-02-16 Smithkline Beecham Corporation Substituted heterocyclic compounds as modulators of the ccr5 receptor
JP4588447B2 (ja) 2002-08-09 2010-12-01 セラヴァンス， インコーポレーテッド 過剰増殖および関連疾患に関連するオンコキナーゼ融合ポリペプチド、これをコードする核酸、ならびにこれを検出する方法および同定する方法
EP1765313A2 (de) 2004-06-24 2007-03-28 Novartis Vaccines and Diagnostics, Inc. Verbindungen als immunstimulatoren
US20070054916A1 (en) * 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
EP1888588A2 (de) * 2005-04-28 2008-02-20 SuperGen, Inc. Proteinkinaseinhibitoren
AU2006269917A1 (en) * 2005-07-20 2007-01-25 Millennium Pharmaceuticals, Inc. New crystal forms of 4-[6-methoxy-7-(3-piperidin-1-yl-propoxy)quinazolin-4-yl]piperazine-1-carboxylic acid(4-isopropoxyphenyl)-amide
AU2007221049A1 (en) * 2006-02-28 2007-09-07 Amgen Inc. Cinnoline and quinazoline derivates as phosphodiesterase 10 inhibitors
UA95641C2 (en) * 2006-07-06 2011-08-25 Эррей Биофарма Инк. Hydroxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
US8198266B2 (en) 2006-10-31 2012-06-12 Inserm (Institut National De La Sante Et De La Recherche Medicale) Use of an EGFR antagonist for the treatment of glomerolonephritis
JP5250901B2 (ja) * 2007-02-23 2013-07-31 学校法人慶應義塾 アニリノキナゾリン系化合物及びその用途
WO2008128072A2 (en) * 2007-04-13 2008-10-23 Supergen, Inc. Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders
US20100273808A1 (en) * 2008-11-21 2010-10-28 Millennium Pharmaceticals, Inc. Lactate salt of 4-[6-methoxy-7-(3-piperidin-1-yl-propoxy)quinazolin-4-yl]piperazine-1-carboxylic acid(4-isopropoxyphenyl)-amide and pharmaceutical compositions thereof for the treatment of cancer and other diseases or disorders
DK3409278T3 (da) 2011-07-21 2020-11-09 Sumitomo Dainippon Pharma Oncology Inc Heterocykliske proteinkinaseinhibitorer
CN102942529B (zh) * 2012-11-09 2015-06-24 贵州大学 4-(4-取代哌嗪)-5,6,7-三烷氧基喹唑啉类化合物及其制备方法和应用
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
CN103288760B (zh) * 2013-05-16 2015-02-18 苏州明锐医药科技有限公司 卡奈替尼的制备方法
WO2015009889A1 (en) 2013-07-18 2015-01-22 Concert Pharmaceuticals, Inc. Deuterated intedanib derivatives and their use for the treatment of proliferative disorders
TWI659021B (zh) 2013-10-10 2019-05-11 亞瑞克西斯製藥公司 Ｋｒａｓ ｇ１２ｃ之抑制劑
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
US10011600B2 (en) 2014-09-25 2018-07-03 Araxes Pharma Llc Methods and compositions for inhibition of Ras
AR102094A1 (es) 2014-09-25 2017-02-01 Araxes Pharma Llc Inhibidores de proteínas kras con una mutación g12c
CN107849022A (zh) 2015-04-10 2018-03-27 亚瑞克西斯制药公司 取代的喹唑啉化合物和其使用方法
EP3283462B1 (de) 2015-04-15 2020-12-02 Araxes Pharma LLC Kondensierte tricyclische inhibitoren von kras und anwendungsverfahren dafür
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
US10730867B2 (en) 2015-09-28 2020-08-04 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2017058915A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3356351A1 (de) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitoren von kras-g12c-mutanten proteinen
EP3356353A1 (de) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitoren von kras-g12c-mutanten proteinen
US10875842B2 (en) 2015-09-28 2020-12-29 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2017058902A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3356359B1 (de) 2015-09-28 2021-10-20 Araxes Pharma LLC Inhibitoren von kras-g12c-mutanten proteinen
EP3364977A4 (de) 2015-10-19 2019-09-04 Araxes Pharma LLC Verfahren zum screening von inhibitoren von ras
EP3377481A1 (de) 2015-11-16 2018-09-26 Araxes Pharma LLC 2-substituierte chinazolinverbindungen mit einer substituierten heterocyclischen gruppe und verfahren zur verwendung davon
US9988357B2 (en) 2015-12-09 2018-06-05 Araxes Pharma Llc Methods for preparation of quinazoline derivatives
WO2017172979A1 (en) 2016-03-30 2017-10-05 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
CN106083715A (zh) * 2016-06-01 2016-11-09 谢阳 一种喹啉、喹唑啉类化合物及其药物组合物和应用
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
WO2018064510A1 (en) 2016-09-29 2018-04-05 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
CN110312711A (zh) 2016-10-07 2019-10-08 亚瑞克西斯制药公司 作为ras抑制剂的杂环化合物及其使用方法
US11274093B2 (en) 2017-01-26 2022-03-15 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
WO2018140514A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
EP3573971A1 (de) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-on-derivate und ähnliche verbindungen als kras-g12c-modulatoren zur behandlung von krebs
EP3573967A1 (de) 2017-01-26 2019-12-04 Araxes Pharma LLC Kondensierte bicyclische hetero-hetero-verbindungen und verfahren zur verwendung davon
WO2018140599A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
CN110869358A (zh) 2017-05-25 2020-03-06 亚瑞克西斯制药公司 Kras的共价抑制剂
EP3630746A1 (de) 2017-05-25 2020-04-08 Araxes Pharma LLC Verbindungen und verwendungsverfahren dafür zur behandlung von krebs
CN110831933A (zh) 2017-05-25 2020-02-21 亚瑞克西斯制药公司 喹唑啉衍生物作为突变kras、hras或nras的调节剂
MX2020010437A (es) 2018-04-05 2021-01-29 Sumitomo Pharma Oncology Inc Inhibidores de axl cinasa y uso de los mismos.
CN108570039B (zh) * 2018-04-25 2022-09-23 上海美迪西生物医药股份有限公司 一类具有抑制抗凋亡蛋白活性的化合物及其制备和应用
US11471456B2 (en) 2019-02-12 2022-10-18 Sumitomo Pharma Oncology, Inc. Formulations comprising heterocyclic protein kinase inhibitors
CN114920704B (zh) * 2019-07-26 2023-11-03 暨南大学 一种苯基哌嗪喹唑啉类化合物或其药学上可接受的盐、制法与用途
CN111773440A (zh) * 2020-05-22 2020-10-16 南京大学 一种基于类酶催化反应的抗凝血材料
WO2023081923A1 (en) 2021-11-08 2023-05-11 Frequency Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0584222B1 (de) 1991-05-10 1997-10-08 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono- und bicyclische aryl- und heteroarylderivate mit inhibierender wirkung auf die egf und/oder pdgf-rezeptor tyrosinkinase
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
TW225528B (de) 1992-04-03 1994-06-21 Ciba Geigy Ag
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
AU719392B2 (en) * 1996-10-01 2000-05-11 Kyowa Hakko Kirin Co., Ltd. Nitrogen-containing heterocyclic compounds
ES2356886T3 (es) * 1998-03-31 2011-04-14 Kyowa Hakko Kirin Co., Ltd. Compuestos heterocíclicos nitrogenados.
EP1309568B1 (de) 2000-08-18 2011-02-16 Millennium Pharmaceuticals, Inc. (Chinazolin-4-yl)piperazin-4-yl]thiocarboxamide als Hemmer der Phosphorylierung eines PDGF-Rezeptors
WO2002016360A2 (en) 2000-08-18 2002-02-28 Cor Therapeutics, Inc. Nitrogenous heterocyclic compounds
AU2001293209A1 (en) 2000-08-18 2002-03-04 Cor Therapeutics, Inc. Nitrogenous heterocyclic compounds
EP2277877A1 (de) * 2000-08-18 2011-01-26 Millennium Pharmaceuticals, Inc. Quinazolinderivate als Kinasehemmer
AU2002254152A1 (en) 2001-03-08 2002-09-24 Millennium Pharmaceuticals (homo) piperazine substituted quinolines for inhibiting the phosphorylation of kinases
WO2003000188A2 (en) * 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel quinazolines and uses thereof
US7456189B2 (en) * 2003-09-30 2008-11-25 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation

Also Published As

Publication number Publication date
EA005809B1 (ru) 2005-06-30
CN1633431A (zh) 2005-06-29
SI1315715T1 (sl) 2008-12-31
CY1110460T1 (el) 2015-04-29
BR0113356A (pt) 2004-04-20
CA2426440C (en) 2011-03-15
US20150133439A1 (en) 2015-05-14
DE60134990D1 (de) 2008-09-04
US20050288297A1 (en) 2005-12-29
HU228668B1 (hu) 2013-05-28
IL154514A (en) 2011-03-31
JP2005501796A (ja) 2005-01-20
EP1964839A3 (de) 2008-11-05
ES2311023T3 (es) 2009-02-01
EP2277877A1 (de) 2011-01-26
US8324205B2 (en) 2012-12-04
NO20030747L (no) 2003-04-14
CZ2003765A3 (cs) 2004-08-18
NO20030747D0 (no) 2003-02-17
AU2001285449B2 (en) 2007-04-05
CN100358890C (zh) 2008-01-02
DK1315715T3 (da) 2008-11-17
EA200300265A1 (ru) 2003-12-25
HUP0302615A3 (en) 2008-03-28
US6982266B2 (en) 2006-01-03
ZA200301510B (en) 2004-06-22
CA2426440A1 (en) 2002-02-28
NZ524461A (en) 2004-12-24
US20050101609A1 (en) 2005-05-12
US20100113468A1 (en) 2010-05-06
IL154514A0 (en) 2003-09-17
PT1315715E (pt) 2008-10-30
KR100831116B1 (ko) 2008-05-20
AU8544901A (en) 2002-03-04
EP1315715A1 (de) 2003-06-04
MXPA03001359A (es) 2004-12-13
EP1315715B1 (de) 2008-07-23
NO323782B1 (no) 2007-07-02
EP1964839A2 (de) 2008-09-03
CZ304061B6 (cs) 2013-09-11
KR20030082537A (ko) 2003-10-22
US20130274252A1 (en) 2013-10-17
WO2002016351A1 (en) 2002-02-28
JP5073147B2 (ja) 2012-11-14
HUP0302615A2 (hu) 2003-12-29
HK1057206A1 (en) 2004-03-19
US7560461B2 (en) 2009-07-14

Similar Documents

Publication Publication Date Title
ATE402169T1 (de) Quinazolin-derivate als kinase inhibitoren
WO2002072578A3 (en) (homo) piperazine substituted quinolines for inhibiting the phosphorylation of kinases
MY134848A (en) Pyrrolo[2,1-f] [1,2,4] triazine inhibitors of kinases
BRPI0513565A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, métodos para inibir uma atividade de proteìna cinase, e para tratar um paciente tendo uma condição que é mediada por atividade de proteìna cinase, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica
WO2004001059A3 (en) Heterocyclic inhibitors of kinases
DK0882717T3 (da) Nitrogenholdige heterocykliske forbindelser
NO20052927L (no) 2,4,6-trisubstituerte pyrimidiner av fosfotidylinositol (PI) 3-kinaseinhibitorer og deres anvendelse ved behandling av kreft
MY145634A (en) Pyrrolotriazine compounds as kinase inhibitors
ATE541833T1 (de) Stickstoff-enthaltende verbindungen mit kinasehemmender wirkung sowie diese enthaltende medikamente
ATE483693T1 (de) N-aryl-ä4-ä7-(alkoxy)chinazolin-4- ylüpiperazinylücarboxamid-verbindungen als pdgf- rezeptoren hemmer
BRPI0407834A (pt) composto, processo para a manufatura do mesmo, composição, processo para a manufatura da mesma, método de tratamento ou prevenção de um distúrbio mediado por proteìna quinase em um indivìduo, uso de um composto, ensaio para determinar a atividade dos compostos, e, método de inibição da atividade ou função de uma proteìna quinase
SG132683A1 (en) Imidazopyrazine tyrosine kinase inhibitors
BRPI0417697A (pt) inibidores de protease de aspartila heterocìclicos
DE60002714D1 (de) Substituierte azaoxindolederivate
WO2002016360A3 (en) Nitrogenous heterocyclic compounds
DE60144050D1 (de) (Chinazolin-4-yl)piperazin-4-ylÜthiocarboxamide als Hemmer der Phosphorylierung eines PDGF-Rezeptors
EA200870454A1 (ru) Способ ингибирования c-kit киназы
FR2725719B1 (fr) Diazepino-indoles inhibiteurs de phosphodiesterases iv
ATE360423T1 (de) Verwendung von chymase hemmern gegen vaskuläre lipidablagerung
ATE421510T1 (de) Kompetitive atp-kinasehemmer
TH48285A (th) อะโทรปไอโซเมอร์ 3-เฮเทอโรอาริล 4(3h) ควินาโซลิโนน

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1315715

Country of ref document: EP